One-Year Outcomes following Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in Japanese Patients: The APOLLO Study

Publisher： Karger

E-ISSN： 1423-0267|238|3|163-171

ISSN： 0030-3755

Source： Ophthalmologica, Vol.238, Iss.3, 2017-07, pp. : 163-171

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

One-Year Results of Intravitreal Ranibizumab with or without Photodynamic Therapy for Polypoidal Choroidal Vasculopathy

By  

Ophthalmologica, Vol. 226, Iss. 3, 2011-07 ,pp. : 119-126

Karger

Access to resources Recommend Favorite

Long-Term Follow-Up of Polypoidal Choroidal Vasculopathy Secondary to Angioid Streaks Treated by Intravitreal Aflibercept and Ranibizumab

By  

Case Reports in Ophthalmology, Vol. 8, Iss. 1, 2017-04 ,pp. : 221-231

Karger

Access to resources Recommend Favorite

Comparison of the 12-Month Outcomes of Intravitreal Ranibizumab between Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy

By  

Ophthalmologica, Vol. 237, Iss. 3, 2017-03 ,pp. : 123-127

Karger

Access to resources Recommend Favorite

Two-Year Results of Photodynamic Therapy Combined with Intravitreal Anti-Vascular Endothelial Growth Factor for Polypoidal Choroidal Vasculopathy

By  

Ophthalmologica, Vol. 226, Iss. 4, 2011-09 ,pp. : 205-213

Karger

Access to resources Recommend Favorite

Stereotactic Radiotherapy for Polypoidal Choroidal Vasculopathy: A Pilot Study

By  

Ophthalmologica, Vol. 233, Iss. 2, 2014-11 ,pp. : 82-88

Karger

Access to resources Recommend Favorite